Proceeding towards Becoming a Contract Producer of Bio-pharmaceuticals～MGC reaches an agreement with U.S.-based Catalent Pharma Solutions～January 5, 2015

MGC Pharma Co., Ltd., a wholly owned subsidiary of Mitsubishi Gas Chemical Company,
Inc. (MGC; Head Office: Chiyoda-ku, Tokyo; President: Toshikiyo Kurai), and Catalent
Pharma Solutions, a leading contract manufacturer of pharmaceuticals (Head Office:Somerset, New Jersey, USA), have entered into an agreement to jointly engage in thecontract research/development, and contract production up to the clinical trial phase, ofbiosimilars*1.

Under the agreement, MGC Pharma will use highly efficient antibody drug producing
cells*2 produced with Catalent’s GPEx® technology to develop processes for biosimilars
used in the treatment of respiratory syncytial virus infections, cancers and rheumatism, withthe aim of winning API production contracts.

Since 2011, MGC has been developing antibody drug operations as a contract researchorganization (CRO) focusing on process development. The new agreement with Catalent
will enable MGC’s contract antibody drug services to provide customers with a one-stop
solution encompassing all phases from cell line development to commercial production, andthereby to proceed to being approved as a contract manufacturing organization (CMO).

*1: Biosimilars
Biosimilars are generic biological drugs featuring quality/ safety levels and efficacies comparable tothose of brand-name products.

*2: Antibody drug producing cells
Antibody drug producing cells produce antibodies that are used as raw materials for antibody drugs. A
category of biological drugs employing the principles of antigen-antibody reaction (immune reaction),antibody drugs are employed primarily to treat cancers and immunological diseases. Compared withconventional low-molecular medicine, they have a higher specificity and therefore cause fewer sideeffects.
<Inquiries>
Natural Gas Chemicals Division Tel: +81-(0)3-3283-4821

＜Reference informations＞

About MGC Pharma
Head office: Mitsubishi Building, 2-5-2 Marunouchi, Chiyoda-ku, Tokyo 100-8324, Japan
Business operations: Contract research and contract production process development for
antibody drugs
Representative : Masami Orisaku, Representative Director, President
Established: April 2, 2014

Employees:11 including directors (as of September 2014)

URL: http://www.mgc-pharma.com/en/index.html

About Catalent Pharma Solutions
Head office: Somerset, New Jersey, USA

Business operations: Contract development, production, supply, and provision ofsolutions for pharmaceuticals used in medical, biotech, andconsumer-health products; contract production of investigational
new drugs
Representative : John Chiminski, President and CEO
Established: April 2007

Employees: 9,000

URL: http://www.catalent.com/index.php

About Catalent Japan
Head office: Akasaka Daiichi Building, 4-19-17 Akasaka, Minato-ku, Tokyo 107-0052,Japan
Business operations: Contract production of soft capsules and contract production ofinvestigational new drugs
Representative : Tadahiro Matsumura, President and Representative Director
Established: October 29, 1974

Employees: 241 (as of December 2014)

URL: http://japan.catalent.com/index.php